| Cas No.: | 2308497-58-5 |
| Chemical Name: | FGFR1/DDR2 inhibitor 1 |
| Synonyms: | FGFR1/DDR2 inhibitor 1;BDBM50529770;3-(3-(1-Cyclopropyl-1H-pyrazol-4-yl)-1H-indazol-6-yl)-4-methyl-N-(3-(trifluoromethyl)phenyl)benzamide;3-(3-(1-cyclopropyl-1h-pyrazol-4-yl)-1h-indazol-6-yl)-N-(3-(trifluoromethyl)phenyl)-4-methylbenzamide |
| SMILES: | FC(C1=CC=CC(=C1)NC(C1C=CC(C)=C(C=1)C1C=CC2=C(C=1)NN=C2C1C=NN(C=1)C1CC1)=O)(F)F |
| Formula: | C28H22F3N5O |
| M.Wt: | 501.50239610672 |
| Purity: | >98% |
| Sotrage: | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Description: | FGFR1/DDR2 inhibitor 1 (compound 11k) is an inhibitor of fibroblast growth factor receptor 1 (FGFR1) and discoindin domain receptor 2 (DDR2), with IC50 values of 31.1 nM, 108.4 nM and 3.2 nM for FGFR1, KG-1, and DDR2, respectively[1]. |
| Target: | IC50: 31.1 nM (FGFR1), 108.4 nM (KG-1), 3.2 nM (DDR2)[1]. |
| References: | [1]. Wang Q, et al. Discovery and optimization of a series of 3-substituted indazole derivatives as multi-target kinase inhibitors for the treatment of lung squamous cell carcinoma. Eur J Med Chem. 2019 Feb 1;163:671-689. |
MSDS
COA
| LOT NO. | DOWNLOAD |
|
|
|
| 2018-0101 |
|
| 2018-0101 |
|
| 2018-0101 |
|